Table 3

HR of haematological malignancy in TNFi-treated versus bDMARD-naïve patients and general population comparators, respectively, for Sweden and Denmark

HR (95% CI)* of haematological malignancy in TNFi-treated versus bDMARD-naïve PsA from the clinical rheumatology register (comparator group 1)HR (95% CI)* of haematological malignancy in TNFi-treated versus bDMARD-naïve PsA from the national patient register
(comparator group 2)		HR (95% CI)* of haematological malignancy in TNFi-treated PsA versus the general population group 1†HR (95% CI)* of haematological malignancy in
PsA overall versus the general population group 2‡
SwedenDenmarkSwedenDenmarkSwedenDenmarkSwedenDenmark
Subjects, n6505 vs
9560		2429 vs
6779		6505 vs
21 629		2429 vs
5657		6505 vs
32 625		2429 vs
12 007		25 980 vs
135 639		10 204 vs
48 898
Person-years36 950 vs
39 058		12 426 vs
21 693		36 950 vs 121 66312 426 vs
23 595		36 950 vs
184 252		12 426 vs
53 334		147 713 vs
900 016		42 379 vs
234 151
Haematological cancer overall, n28 vs 317 vs 2828 vs 1457 vs 2728 vs 1107 vs 15162 vs 71648 vs 192
HR (95% CI)        
 Crude1.33
(0.79 to 2.22)		0.59
(0.25 to 1.36)		0.89
(0.59 to 1.33)		0.72
(0.31 to 1.69)		1.25
(0.83 to 1.89)		2.28
(0.89 to 5.86)		1.30
(1.10 to 1.55)		1.37
(0.99 to 1.90)
 Adjusted for sex, age and calendar time1.33
(0.79 to 2.22)		0.54
(0.23 to 1.29)		0.90
(0.60 to 1.35)		0.71
(0.30 to 1.67)		1.25
(0.83 to 1.89)		2.28
(0.89 to 5.86)		1.30
(1.09 to 1.54)		1.37
(0.99 to 1.90)
 Adjusted for sex, age and calendar time and excluding first year of follow-up1.19 (0.68 to 2.08)0.56 (0.22 to 1.44)0.93 (0.59 to 1.47)0.78 (0.31 to 1.98)1.23 (0.78 to 1.94)1.96
(0.75 to 5.17)		1.19 (0.99 to 1.44)1.24 (0.86 to 1.79)

  • Bold values = statistically significant with 95% confidence intervals.

  • *Multivariate Cox regression with HR with 95% CI adjusted for sex and calendar period (2006–2010, 2011-end of follow-up) with attained age as time scale.

  • †General population group 1: Each TNFi treated patients with PsA are matched 1:5 on age, sex and calendar period to five comparators from the general population. For Sweden also matched to area of residence. The follow-up begins at the start of TNFi for the patients with PsA and at the same date for their general population comparators.

  • ‡This PsA group includes all patients with PsA identified in the national patient register (NPR) and/or in clinical rheumatology register (CRR) irrespective of treatment. General population group 2: Each of the patients with PsA are matched 1:5 on age, sex, calendar period to the five comparators from the general population. For Sweden also matched to area of residence. Start of follow-up for the patients with PsA is whichever comes first of a first visit with PsA diagnosis in NPR, the inclusion date in CRR with a diagnosis of PsA or initiating a first TNFi according to CRR. Start of follow-up for the gen pop comparator was at the same date as start of follow-up of their index PsA patient.

  • N/A, Not available; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.